Adverse event reporting requires safety teams to make several decisions within defined regulatory timelines: medical review, seriousness assessment, causality assessment, MedDRA coding, expectedness evaluation, and, where applicable, expedited submission. These steps typically draw on input from investigators, clinical operations, data management, and pharmacovigilance staff. Well-run adverse event reporting clinical trials processes depend on more than speed — the operational challenge is reaching the right reporting decision while keeping a traceable record of how that decision was made.
What Makes an Adverse Event Reportable
Not every adverse event occurring during a trial triggers expedited reporting. The applicable pathway depends on seriousness, whether the event is suspected to relate to the investigational product, and whether the reaction is expected given existing safety information. ICH E2A distinguishes an adverse event from an adverse drug reaction based on whether there is at least a reasonable possibility of a causal relationship, and it establishes the concepts used for expedited reporting of significant safety findings during development.
In the United States, FDA generally requires serious and unexpected suspected adverse reactions that meet applicable reporting criteria to be reported within 15 calendar days after the sponsor determines that the information qualifies for reporting, while unexpected fatal or life-threatening suspected adverse reactions must be reported as soon as possible and no later than seven calendar days after the sponsor initially receives the information. This makes case triage a meaningful control point: safety teams need to capture exactly when relevant information was first received and whether further information is needed before a reporting decision can be finalized.
Managing SUSAR Timelines Across Regions
SUSAR timelines should be tracked from the point a sponsor becomes aware of information triggering the relevant requirement. In the EU, SUSARs are submitted through EudraVigilance, while other safety information affecting a trial’s benefit-risk balance follows a separate pathway. EU SUSAR timelines mirror the US structure in broad terms — seven days for fatal or life-threatening cases, 15 days for others — with follow-up reports required if new information changes a previously reported case’s interpretation.
This means a case-management system should not rely on a single final database entry date alone. The dates of initial awareness, case qualification, medical review, submission, and any follow-up information all need to remain traceable, and cases awaiting source information or review can be flagged automatically so responsible staff can intervene before a deadline is at risk.
Why MedDRA Coding and Causality Assessment Are Separate Tasks
MedDRA coding provides standardized terminology across several hierarchical levels — from Lowest Level Terms up to System Organ Classes — so that safety information can be organized consistently for later retrieval and reporting. Selecting the correct level is part of the coding judgment itself, and MedDRA’s own Points to Consider guidance cautions against coding a more specific diagnosis than the reported information actually supports. Version control also matters, since MedDRA updates periodically and safety organizations need a defined process for implementing and documenting terminology changes across ongoing studies.
Causality assessment is a distinct activity from coding: it weighs the timing of exposure and onset, the patient’s underlying condition, concomitant medications, biological plausibility, and any dechallenge or rechallenge information, rather than simply naming the medical concept involved. Because conclusions can change once follow-up information arrives, the process should preserve both the current conclusion and the evidence behind it, giving a clearer audit trail than recording only a final classification.
Expedited Reporting Versus Aggregate Safety Review
Expedited and aggregate reporting answer different questions. Expedited reports address individual qualifying cases requiring prompt regulatory attention, while aggregate assessments — such as the Development Safety Update Report FDA permits for certain annual IND obligations — examine accumulated data over time to identify trends and evaluate the evolving safety profile. Safety databases need to support both functions simultaneously, since the quality of individual case data directly affects the reliability of later aggregate analysis.
Where Automation and Experienced Support Fit
Automation can reduce administrative error by handling deadline calculation, task assignment, duplicate detection, follow-up reminders, and escalation alerts, while leaving medical judgment to qualified reviewers. Electronic transmission under the ICH E2B(R3) standard supports more structured, interoperable reporting, particularly for safety teams managing cases across multiple regions and reporting authorities. Automation should not, however, be mistaken for automated medical decision-making — determining whether an event is a suspected adverse reaction still requires professional interpretation.
Sponsors evaluating pharmacovigilance services for this kind of work are generally advised to look beyond raw case-processing capacity, considering medical review capability, regulatory knowledge, database experience, and quality controls. Tigermed’s own pharmacovigilance service covers clinical-trial preparation, case management, safety-management planning, database setup, DSUR drafting and review, and risk-management planning, alongside pharmacovigilance system setup, data security, and audit and inspection support. The company reports more than 200 global pharmacovigilance professionals, over 2,000 project experiences, and more than 300 global partners on its own service page — company-reported figures worth weighing alongside a sponsor’s specific therapeutic and regulatory needs.
Building a More Efficient Reporting Process
An efficient workflow starts with clear decision points rather than added processing capacity alone: intake that captures the reporting clock, triage that flags serious cases early, medical review focused on causality, and coding that accurately reflects the reported concept. Quality controls — duplicate checks, deadline monitoring, documented review steps, and audit trails — should run throughout, with automation reducing manual administrative work rather than shortening medical assessment itself.
The most sustainable model generally combines regulatory timelines, standardized terminology, documented medical judgment, structured electronic reporting, and proportionate automation, keeping routine pharmacovigilance activity integrated with the broader clinical development process. Companies such as Tigermed, which report a multi-region pharmacovigilance team alongside this kind of structured service offering, illustrate one way sponsors can look for this level of integration in a partner.
